Vous avez cherché: naloksona (Croate - Anglais)

buprenorfina/naloksona niti
or victrelis is

prilagodba doze buprenorfina/naloksona nije potrebna.
no dose adjustment of buprenorphine/naloxone is required.

dodavanje naloksona pomaže pri sprječavanju zlouporabe lijeka.
the addition of naloxone helps prevent the misuse of the medicine.

može ih slijediti primjena specifičnog opioidnog antagonista poput naloksona.
these actions can be followed by administration of a specific opioid antagonist such as naloxone.

naloksegol je pegilirani derivat antagonista mi-opioidnog receptora naloksona.
naloxegol is a pegylated derivative of the mu-opioid receptor antagonist naloxone.

ako je potrebno vaš će veterinar primijeniti više od jedne doze naloksona vašem psu.
if needed, your veterinarian might administer more than one dose of naloxone to your dog.

nema dovoljno dokaza za preporuku primjene naloksona u liječenju predoziranja ghb-om.
there is insufficient evidence to recommend the use of naloxone in the treatment of overdose with ghb.

nadalje, uporabu buprenorfina/naloksona tijekom trudnoće trebao bi odobriti liječnik.
furthermore, the use of buprenorphine/naloxone during pregnancy should be assessed by the physician.

sigurnost i djelotvornost buprenorfina/naloksona u bolesnika starijih od 65 godina nije ustanovljena.
the safety and efficacy of buprenorphine/naloxone in elderly patients over 65 years of age have not been established.

naloksegol se dobiva od naloksona, dobro poznate tvari koja se koristi za onemogućavanje djelovanja opioida.
naloxegol is derived from naloxone, a well-known substance that is used to block the action of opioids.

primarna usporedba u ispitivanju bila je procjena djelotvornosti buprenorfina i buprenorfina/naloksona naspram placeba.
the primary study comparison was to assess the efficacy of buprenorphine and buprenorphine/naloxone individually against placebo.

primjena naloksona od 0,04 mg/kg može se upotrijebiti za oporavak od nuspojava povezanih s topičkim fentanilom.
administration of naloxone at 0.04 mg/kg may be used to reverse adverse reactions associated with topical fentanyl.

eliminacija putem bubrega ima relativno malu ulogu (~30 %) u ukupnom klirensu buprenorfina/naloksona.
renal elimination plays a relatively small role (~30 %) in the overall clearance of buprenorphine/naloxone.

kombinacija buprenorfina i naloksona ispitivana je u ispitivanjima akutne i toksičnosti ponovljenih doza u životinja (do 90 dana u štakora).
the combination of buprenorphine and naloxone has been investigated in acute and repeated dose (up to 90 days in rats) toxicity studies in animals.

bolesnici moraju biti pod nadzorom zbog znakova i simptoma ustezanja od opioida, toksičnosti ili predoziranja uzrokovanih povišenom razinom naloksona i/ili buprenorfina.
patients should be monitored for signs and symptoms of precipitated opioid withdrawal, toxicity or overdose caused by increased levels of naloxone and/or buprenorphine.

sveukupno, izloženost buprenorfinu u plazmi povećana je približno 3 puta, a izloženost naloksona u plazmi povećana je 14 puta u bolesnika s teškim oštećenjem funkcije jetre.
overall, buprenorphine plasma exposure increased approximately 3-fold in patients with severely impaired hepatic function, while naloxone plasma exposure increased 14-fold with severely impaired hepatic function.

davanjem buprenorfina/naloksona zajedno s hranom u štakora pri dozi od 500 ppm ili višoj smanjila se plodnost, što se pokazalo smanjenjem stopa začeća u ženki štakora.
dietary administration of buprenorphine in the rat at dose levels of 500 ppm or greater produced a reduction in fertility demonstrated by reduced female conception rates.

međutim, kad ga intravenski primjenjuju osobe ovisne o opioidima, prisutnost naloksona u lijeku suboxone izaziva izrazite učinke opioidnog antagonista i ustezanja od opioida, što odvraća osobe od intravenske zlouporabe.
however, when administered intravenously to opioid-dependent persons, the presence of naloxone in suboxone produces marked opioid antagonist effects and opioid withdrawal, thereby deterring intravenous abuse.

bolesnici ovisni o heroinu ili kratkodjelujućim opioidima, prvu dozu buprenorfina/naloksona trebaju uzeti kad se pojave znakovi ustezanja, ali ne prije nego što je proteklo 6 sati nakon zadnjeg uzimanja opioida.
for patients dependent upon heroin or short-acting opioids, the first dose of buprenorphine/naloxone should be taken when signs of withdrawal appear, but not less than 6 hours after the patient last used opioids.

nakon peroralne primjene, nalokson se jedva može izmjeriti u plazmi; nakon sublingvalne primjene buprenorfina/naloksona, koncentracije naloksona u plazmi su niske i brzo se smanjuju.
following oral administration, naloxone is barely detectable in plasma; following sublingual administration of buprenorphine/naloxone, plasma naloxone concentrations are low and decline rapidly.